Aptose BiosciencesAPTO
Market Cap: $6.57M
About: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Employees: 36
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
22% more capital invested
Capital invested by funds: $1.74M [Q1] → $2.12M (+$382K) [Q2]
8.72% more ownership
Funds ownership: 6.65% [Q1] → 15.38% (+8.72%) [Q2]
15% less funds holding
Funds holding: 27 [Q1] → 23 (-4) [Q2]
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 1,829%upside $7 | Buy Reiterated | 14 Jun 2024 |
Financial journalist opinion
Based on 3 articles about APTO published over the past 30 days